Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in <i>EGFR</i> Mutation–Positive Non–Small Cell Lung Cancer
Kohsuke Isomoto(Kindai University Hospital), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Yasutaka Chiba(Kindai University Hospital), Toshihide Yokoyama(Kurashiki Central Hospital), Hidetoshi Hayashi(Kindai University), Shuta Tomida(Okayama University), Koji Haratani(Dana-Farber Cancer Institute), Junko Tanizaki(Kindai University Sakai Hospital), Akihiko Ito(Kobe University), Masayuki Takeda(Kindai University), Takashi Ogura(Saiseikai Utsunomiya hospital), Tadashi Ishida(Kurashiki Central Hospital), Ryoji Kato(Kindai University), Kaoru Tanaka(Kindai University), Takashi Niwa(Kurashiki Central Hospital), Yasushi Fukuda(Kurashiki Central Hospital), Shigeki Shimizu(Kindai University)
Cited by 244
Related Papers
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Reduced Expression of the <b> <i>let-7</i> </b> MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival
|Cancer Research|2004|2.4k